“Lenvatinib is More Effective & Safer Than Sorafenib in the Treatment of Renal Cell Carcinoma - A Single-Center Retrospective Analysis of 70 Cases” (2024) Journal of Carcinogenesis, 23(1), pp. 624–628. doi:10.64149/J.Carcinog.23.1.624-628.